What is the primary purpose of this 8-K filing?

This 8-K filing announces Amgen Inc.'s financial results for the three and twelve months ended December 31, 2003. Its main focus is on explaining the company's use of non-GAAP financial measures and the specific adjustments made to GAAP figures, primarily related to the acquisition of Immunex Corporation and other significant events.

Why is Amgen using non-GAAP financial measures?

Amgen uses non-GAAP financial measures to provide investors with supplementary information that it believes offers a clearer view of the company's ongoing operational performance. These adjustments help to exclude the impact of one-time or non-recurring items, making it easier to compare financial results across different periods.

What types of adjustments are being made to the GAAP figures?

Adjustments include items like incremental compensation for former Immunex employees, amortization of acquired intangible assets (such as Enbrel®), costs and settlements related to litigation (Genentech, Johnson & Johnson), integration costs from the Immunex acquisition, and contributions to the Amgen Foundation. The specific adjustments vary between the 2003 and 2002 periods.

How do these adjustments affect the comparability of financial results?

Amgen believes these adjustments enhance comparability by isolating core operational performance. For example, excluding amortization of acquired intangibles aims to treat acquired intellectual property similarly to internally developed intellectual property, and excluding one-time litigation or integration costs allows for clearer period-over-period operational trend analysis.

AMGN 8-K SEC Disclosure

Summary

Amgen Inc. filed an 8-K on January 29, 2004, to announce its financial results for the fourth quarter and full year ended December 31, 2003. The report primarily details the company's use of non-GAAP financial measures, which adjust for significant one-time or non-recurring items related to the acquisition of Immunex Corporation and other specific events. These adjustments are intended to provide investors with a clearer view of the company's ongoing operational performance and facilitate period-over-period comparisons. Key adjustments for 2003 include incremental compensation for former Immunex employees, amortization of acquired intangible assets (notably related to Enbrel®), a settlement with Genentech, Inc., a cost recovery from Johnson & Johnson, and a contribution to the Amgen Foundation. Similarly, 2002 adjustments address the Immunex acquisition integration costs, a termination benefit, a legal award from Johnson & Johnson, and another foundation contribution. Amgen utilizes these non-GAAP measures for internal budgeting and financial planning, believing they offer valuable supplementary insights for investors.

Key Highlights

1Amgen reported its financial results for the fourth quarter and full year ended December 31, 2003, via an 8-K filing on January 29, 2004.
2The company prominently uses non-GAAP financial measures to present its results, adjusting for items related to the acquisition of Immunex Corporation.
3Key adjustments for 2003 include incremental employee compensation, amortization of acquired intangibles, a Genentech litigation settlement, and cost recovery from Johnson & Johnson.
4For 2002, adjustments relate to Immunex acquisition integration costs, a legal award from Johnson & Johnson, and other one-time items.
5Amgen emphasizes that these non-GAAP measures are supplementary to GAAP results and aid in understanding ongoing operational performance.
6The company believes excluding certain charges, like amortization of acquired intangibles (e.g., Enbrel®), treats acquired assets similarly to internally developed ones.
7Disclosure also includes non-GAAP sales for Enbrel® for the full year 2002, incorporating Immunex's pre-acquisition sales to show full-year comparability.

AMGEN INC 8-K Report (Jan 29, 2004)

Summary

Key Highlights

Frequently Asked Questions